India Pharma Market Grows 12.1% in July, Led by Zydus Lifesciences and Sun Pharma

$SUNPHARMA India’s pharmaceutical market grew 12.1% year-on-year in July 2026, marking a strong recovery after subdued growth. According to Analyst latest note, the market has maintained double-digit growth, supported by price increases, new product launches and improving volumes. Sales growth in July was driven by a 6% increase in prices. The recovery was supported by a favourable low volume base, higher contributions from new launches such as GLP-1 drugs, and stronger demand across chronic therapies, including cardiac and neurological treatments, as well as VMNs and oncology. Zydus Lifesciences and Sun Pharma recorded the strongest year-on-year growth in July in value terms. On a moving annual total basis, Torrent Pharma led growth at 14.4%, followed by Glenmark and Zydus Lifesciences at 14.2% each. Among major therapy segments, anti-diabetes recorded the fastest growth in July, followed by vitamins, minerals and nutrients (VMNs). Anti-diabetes growth was largely driven by new product launches, with GLP-1 therapies accounting for around 48% of the segment’s growth. VMN growth, meanwhile, was primarily price-led. Cardiac, respiratory, pain, neurology and gynaecology therapies also posted double-digit growth. In contrast, gastro, anti-infectives and dermatology witnessed muted single-digit growth, mainly due to weak volume growth, according to Pharmarack data. At the company level, IPCA Laboratories benefited from strong double-digit growth in pain and cardiology, although weakness in anti-malaria and anti-infective products weighed on overall performance. Growth was relatively subdued for Mankind Pharma, Emcure.